Raltitrexed

Raltitrexed is an antimetabolite agent used in chemotherapy, acting by inhibiting thymidylate synthase.

Product Specifications

CAS Number

[112887-68-0]

Product Name Alternative

ZD1694; D1694; ICI-D1694

UNSPSC

12352005

Hazard Statement

H300, H360

Target

Nucleoside Antimetabolite/Analog; Thymidylate Synthase

Type

Reference compound

Related Pathways

Apoptosis; Cell Cycle/DNA Damage

Applications

Cancer-programmed cell death

Field of Research

Cancer

Assay Protocol

https://www.medchemexpress.com/Raltitrexed.html

Concentration

10mM

Purity

99.51

Solubility

DMSO : ≥ 29 mg/mL

Smiles

CC(NC1=O)=NC2=C1C=C(CN(C)C3=CC=C(C(N[C@H](C(O)=O)CCC(O)=O)=O)S3)C=C2

Molecular Formula

C21H22N4O6S

Molecular Weight

458.49

Precautions

H300, H360

References & Citations

[1]Zhao H, et al. Raltitrexed Inhibits HepG2 Cell Proliferation via G0/G1 Cell Cycle Arrest. Oncol Res. 2016;23 (5) :237-48|[2]Dong Y, et al. Raltitrexed's effect on the development of neural tube defects in mice is associated with DNA damage, apoptosis, and proliferation. Mol Cell Biochem. 2015 Jan;398 (1-2) :223-31.|[3]Xue S, et al. Raltitrexed induces mitochondrial-mediated apoptosis in SGC7901 human gastric cancer cells. Mol Med Rep. 2014 Oct;10 (4) :1927-34.|[4]Waldman BC, et al. Induction of intrachromosomal homologous recombination in human cells by raltitrexed, an inhibitor of thymidylate synthase. DNA Repair (Amst) . 2008 Oct 1;7 (10) :1624-35.